EUVIMEDEUVIMED entdecken
Kontrollierte klinische Studie

Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial

Ruzeng Xue, Guomin Li, Yao Zhou, Bocheng Wang, Yingping Xu, Peizhen Zhao, Lijun Teng, Jinjin Zheng, Hongfang Liu, Suyun Ji, Dirk M Elston, Yunsheng Liang

Journal of the American Academy of Dermatology · 2024-12 · 91 (6) · 1113-1117

DOI: 10.1016/j.jaad.2024.08.033 ↗

Kurz gefasst

Kontrollierte klinische Studie in der Zeitschrift Journal of the American Academy of Dermatology, 2024-12. Verfasst von Ruzeng Xue und 11 weiteren Autor:innen. Beteiligte Einrichtung: First School of Clinical Medicine, Southern Medical University, Guangzhou, China; Department of Dermatology, Dermatology Hospital, Southern Medical U…. Hauptthemen laut MEDLINE: Interleukin-2, Pemphigoid, Bullous. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Regulatory T cells (Tregs) are reduced in the peripheral blood and skin lesions of patients with bullous pemphigoid (BP). Low-dose interleukin 2 (IL-2) therapy can stimulate Tregs specifically, suggesting potential for the treatment of BP. OBJECTIVE: To evaluate the response to low-dose IL-2 therapy in the treatment of moderate-to-severe BP. METHODS: Forty-three patients with moderate-to-severe BP were included. The therapy included systemic corticosteroids with an initial dose of 0.5 mg/kg/d for moderate and 1.0 mg/kg/d for severe disease, respectively, combined with allowed immunosuppressants for the control group, whereas in addition to the same corticosteroid therapy, IL-2 (half million IU) was administered subcutaneously every other day for the treatment group for 8 weeks. The primary outcome was the number of days required to achieve disease control. Secondary outcomes included other clinical responses. RESULTS: The number of days required to achieve disease control with the treatment group was (7.60 ± 3.00), which was shorter than in the control group (10.43 ± 3.06) (P = .008). The total amount of systemic corticosteroids was less, and no serious infections were detected in the treatment group. LIMITATIONS: Single center, open-label study with short duration and small size. CONCLUSION: Our trial supports the potential of low-dose IL-2 therapy for patients with moderate-to-severe BP, which showed earlier treatment responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-2Pemphigoid, BullousAgedAged, 80 and overFemaleHumansMaleMiddle AgedDrug Therapy, CombinationImmunosuppressive AgentsInjections, SubcutaneousSeverity of Illness IndexT-Lymphocytes, RegulatoryTreatment Outcome

Stichwörter der Autor:innen

BPDAITreg cellsbullous pemphigoidclinical responseconventional therapydisease control daysefficacyinfectionlow-dose interleukin 2 therapysafety

Substanzen

Immunosuppressive AgentsInterleukin-2

Autor:innen und Institutionen

  • First School of Clinical Medicine, Southern Medical University, Guangzhou, China; Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China.
  • Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China.
  • Dermatology Hospital, Southern Medical University, Guangzhou, China.
  • Department of Dermatology, Medical University of South Carolina, Charleston, South Carolina. Electronic address: elstond@musc.edu.
  • Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China. Electronic address: yunshengliang@aliyun.com.

Zitieren

APA

Xue, R., Li, G., Zhou, Y., Wang, B., Xu, Y., Zhao, P., Teng, L., Zheng, J., Liu, H., Ji, S., Elston, D. M., & Liang, Y. (2024). Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial. Journal of the American Academy of Dermatology, 91(6), 1113-1117. https://doi.org/10.1016/j.jaad.2024.08.033

Vancouver

Xue R, Li G, Zhou Y, Wang B, Xu Y, Zhao P, et al. Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial. Journal of the American Academy of Dermatology. 2024;91(6):1113-1117. doi:10.1016/j.jaad.2024.08.033

BibTeX
@article{Xue2024,
  author = {Xue, Ruzeng and Li, Guomin and Zhou, Yao and Wang, Bocheng and Xu, Yingping and Zhao, Peizhen and Teng, Lijun and Zheng, Jinjin and Liu, Hongfang and Ji, Suyun and Elston, Dirk M and Liang, Yunsheng},
  title = {Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial},
  journal = {Journal of the American Academy of Dermatology},
  year = {2024},
  volume = {91},
  number = {6},
  pages = {1113--1117},
  doi = {10.1016/j.jaad.2024.08.033}
}
Kostenlos starten →